INJE PharmacoGenomics Research Center

· Long NP, Anh NK, Yen NTH, Phat NK, Park SO, Thu VTA, Cho YS, Shin JG, Oh JY, Kim DH

Comprehensive lipid and lipid-related gene investigations of host immune responses to characterize metabolism-centric biomarkers for pulmonary tuberculosis (cPMTb)

Sci Rep. 12(1):13395 / 2022.08 [LINK]

· Lee SM, Kim CE, Park HY, Yoon EH, Won HJ, Ahn JM, Nguyen NZN, Kim MJ, Jang WH, Lee WS, Kang MS, Jeong MG, Yun HY, Park SH, Wu SW, Kim DH, Kwon BS, Seo SK

Aryl hydrocarbon receptor-targeted therapy for CD4+ T cell-mediated idiopathic pneumonia syndrome in mice (cPMTb)

Blood. 139(22):3325-3339 / 2022.06 [LINK]

· Jayanti RP, Long NP, Phat NK, Cho YS, Shin JG

Semi-Automated Therapeutic Drug Monitoring as a Pillar toward Personalized Medicine for Tuberculosis Management (cPMTb)

Pharmaceutics. 14(5):990 / 2022.05 [LINK]

· Soedarsono S, Jayanti RP, Mertaniasih NM, Kusmiati T, Permatasari A, Indrawanto DW, Charisma AN, Yuliwulandari R, Long NP, Choi YK, Pham QH, Pham VH, Cho YS, Shin JG

Development of population pharmacokinetics model of isoniazid in Indonesian patients with tuberculosis (cPMTb)

Int J Infect Dis. 117:8-14 / 2022.04 [LINK]

· Jony MR, Cho YS, Long NP, Shin HJ, Shin JG

Characterization of Clofazimine as a Potential Substrate of Drug Transporter (cPMTb)

Antimicrob Agents Chemother. 66(4):e0215821 / 2022.04 [LINK]

· Nguyen VL, Ahn SJ, Hoa PQ, Long NP, Ahn SZ, Cho YS, Shin JG

Center for Personalized Precision Medicine for Tuberculosis: Smart Research and Development Workstation (cPMTb)

Healthc Inform Res. 28(2):176-180 / 2022.04 [LINK]

· Do TH, Duong TH, Nguyen TH, Nguyen TH, Sichaem J, Nguyen CH, Nguyen HH, Long NP

Biological Activities of Lichen-Derived Monoaromatic Compounds (cPMTb)

Molecules. 27(9):2871 / 2022.04 [LINK]

· Cho YS, Shin JG

Physiologically-based pharmacokinetic modeling of nafamostat to support dose selection for treatment of pediatric patients with COVID-19 (cPMTb)

Transl Clin Pharmacol. 30(1):24-36 / 2022.03 [LINK]

· Long NP, Oh JH, Park SM, Yen NTH, Phat NK, Cho YS, Kim HM, Yoon SJ, Shin JG, Kim DH

Delineation of the molecular mechanisms underlying Colistin-mediated toxicity using metabolomic and transcriptomic analyses (cPMTb)

Toxicol Appl Pharmacol. 15:439:115928 / 2022.03 [LINK]

· Parvez MM, Kalkisim S, Nguyen PTT, Jung JA, Park JK, Ghim JL, Kim EY, Cho YS, Babaoglu MO, Shin JG

Para-aminosalicylic acid significantly reduced tenofovir exposure in human subjects: Mismatched findings from in vitro to in vivo translational research (cPMTb)

Br J Clin Pharmacol. 88(3):1159-1169 / 2022.03 [LINK]

Publications

Product